However, for any number of reasons, “floxing away” EBF1 from adipocytes in humans—even if it were feasible at this time—seems questionable, whereas global lack of EBF1 would likely severely compromise an obese patient’s immune system, all the more undesired with the current COVID-19 pandemic. The gene discussed is EBF1; the disease is COVID-19.